Global Hyperlipidemia Drugs Market by Drug Class (Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors), Route of Administration (Oral, Parenteral), Sales Channel - Forecast 2024-2030- Product Image

Sale

Global Hyperlipidemia Drugs Market by Drug Class (Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors), Route of Administration (Oral, Parenteral), Sales Channel - Forecast 2024-2030

Report
196 Pages
March 2024
Region: Global
360iResearch™
ID: 5888967

UP TO €845EUR$875USD£723GBP OFF until Dec 31^st 2024

The Hyperlipidemia Drugs Market size was estimated at USD 23.05 billion in 2023, USD 24.31 billion in 2024, and is expected to grow at a CAGR of 4.24% to reach USD 30.84 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hyperlipidemia Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hyperlipidemia Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hyperlipidemia Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Afton Pharma, Alnylam Pharmaceuticals, Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Daiichi Sankyo Company, Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ionis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Morepen Laboratories Ltd., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Market Segmentation & Coverage

This research report categorizes the Hyperlipidemia Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- PCSK9 Inhibitors
- Statins
Route of Administration
- Oral
- Parenteral
Sales Channel
- Offline
  - Hospitals Pharmacies
  - Retail Pharmacies
- Online

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Hyperlipidemia Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hyperlipidemia Drugs Market?
What are the technology trends and regulatory frameworks in the Hyperlipidemia Drugs Market?
What is the market share of the leading vendors in the Hyperlipidemia Drugs Market?
Which modes and strategic moves are suitable for entering the Hyperlipidemia Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Hyperlipidemia Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing cases of hyperlipidemia across the globe
5.1.1.2. Increasing investment in healthcare infrastructure across the economies
5.1.2. Restraints
5.1.2.1. High cost of raw materials used in formulation of hyperlipidemia drugs
5.1.3. Opportunities
5.1.3.1. Ongoing research and development activities to develop novel hyperlipidemia drugs
5.1.3.2. Expanded availability of hyperlipidemia drugs with patent expiration
5.1.4. Challenges
5.1.4.1. Strict regulatory policies associated with the clinical investigation of drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Hyperlipidemia Drugs Market, by Drug Class

6.1. Introduction
6.2. Bile Acid Sequestrants
6.3. Cholesterol Absorption Inhibitors
6.4. PCSK9 Inhibitors
6.5. Statins

7. Hyperlipidemia Drugs Market, by Route of Administration

7.1. Introduction
7.2. Oral
7.3. Parenteral

8. Hyperlipidemia Drugs Market, by Sales Channel

8.1. Introduction
8.2. Offline
8.3.1. Hospitals Pharmacies
8.3.2. Retail Pharmacies
8.3. Online

9. Americas Hyperlipidemia Drugs Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Hyperlipidemia Drugs Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Hyperlipidemia Drugs Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. Afton Pharma
13.1.3. Alnylam Pharmaceuticals, Inc.
13.1.4. Amgen Inc.
13.1.5. AstraZeneca PLC
13.1.6. Bristol-Myers Squibb Company
13.1.7. Cadila Pharmaceuticals Limited
13.1.8. Daiichi Sankyo Company, Limited
13.1.9. Dr. Reddy’s Laboratories Ltd.
13.1.10. Eli Lilly and Company
13.1.11. F. Hoffmann-La Roche Ltd.
13.1.12. GlaxoSmithKline PLC
13.1.13. Ionis Pharmaceuticals, Inc.
13.1.14. Johnson & Johnson Services, Inc.
13.1.15. Lupin Limited
13.1.16. Merck & Co., Inc.
13.1.17. Morepen Laboratories Ltd.
13.1.18. Novartis AG
13.1.19. Pfizer Inc.
13.1.20. Regeneron Pharmaceuticals, Inc.
13.1.21. Sanofi S.A.
13.1.22. Sun Pharmaceutical Industries Limited
13.1.23. Takeda Pharmaceutical Company Limited
13.1.24. Teva Pharmaceutical Industries Ltd.
13.1.25. Viatris Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. HYPERLIPIDEMIA DRUGS MARKET RESEARCH PROCESS
FIGURE 2. HYPERLIPIDEMIA DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. HYPERLIPIDEMIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. HYPERLIPIDEMIA DRUGS MARKET DYNAMICS
FIGURE 7. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
FIGURE 12. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. HYPERLIPIDEMIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. HYPERLIPIDEMIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. HYPERLIPIDEMIA DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. HYPERLIPIDEMIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY CHOLESTEROL ABSORPTION INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 11. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 14. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 16. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 32. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. CANADA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 36. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. MEXICO HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. AUSTRALIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 54. CHINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. CHINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. CHINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. CHINA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 58. INDIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. INDIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. INDIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. INDIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 62. INDONESIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. INDONESIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. INDONESIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 66. JAPAN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. JAPAN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. JAPAN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. JAPAN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 70. MALAYSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. MALAYSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. MALAYSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 74. PHILIPPINES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. PHILIPPINES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. PHILIPPINES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 78. SINGAPORE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. SINGAPORE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. SINGAPORE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 82. SOUTH KOREA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. SOUTH KOREA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. SOUTH KOREA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 86. TAIWAN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. TAIWAN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. TAIWAN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 90. THAILAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. THAILAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. THAILAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. THAILAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 94. VIETNAM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. VIETNAM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. VIETNAM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. DENMARK HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 107. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. EGYPT HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 111. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. FINLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 115. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. FRANCE HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 119. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. GERMANY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 123. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 127. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ITALY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 131. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 135. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 139. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. NORWAY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 143. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. POLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 147. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. QATAR HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 163. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SPAIN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 167. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 171. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 175. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. TURKEY HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM HYPERLIPIDEMIA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 187. HYPERLIPIDEMIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 188. HYPERLIPIDEMIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 189. HYPERLIPIDEMIA DRUGS MARKET LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
Afton Pharma
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
AstraZeneca PLC
Bristol-Myers Squibb Company
Cadila Pharmaceuticals Limited
Daiichi Sankyo Company, Limited
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline PLC
Ionis Pharmaceuticals, Inc.
Johnson & Johnson Services, Inc.
Lupin Limited
Merck & Co., Inc.
Morepen Laboratories Ltd.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Sanofi S.A.
Sun Pharmaceutical Industries Limited
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Viatris Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	196
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 24.31 Billion
Forecasted Market Value ( USD ) by 2030	$ 30.84 Billion
Compound Annual Growth Rate	4.2%
Regions Covered	Global
No. of Companies Mentioned	25

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3259EUR$3,374USD£2,789GBP €3621EUR$3,749USD£3,099GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4128EUR$4,274USD£3,533GBP €4587EUR$4,749USD£3,925GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€4997EUR$5,174USD£4,276GBP €5552EUR$5,749USD£4,752GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5866EUR$6,074USD£5,020GBP €6518EUR$6,749USD£5,578GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7605EUR$7,874USD£6,508GBP €8450EUR$8,749USD£7,231GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Hyperlipidemia Drugs - Global Strategic Business Report

Hyperlipidemia - Pipeline Insight, 2024

Hyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Antihyperlipidemic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Global Antihyperlipidemic Drugs Market Report and Forecast 2024-2032

About the Hyperlipidemia Drug Market